Aptevo Therapeutics Inc. (APVO) Technical Analysis & Indicators

Aptevo Therapeutics Inc. (APVO) — Price $1.72 HealthcareBiotechnology — NASDAQ

Latest reported results:

Technical analysis of Aptevo Therapeutics Inc. (APVO): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes.

Price Performance

1 month-40.69%
3 months-63.17%
Year-to-date-81.76%
1 year-93.22%
3 years-100.00%
5 years-100.00%

52-Week Range

52-week High$48.78
52-week Low$1.37
Avg Volume (90d)83K

Technical Indicators

SMA 50$3.32
SMA 200$6.72
Beta1.51
30-day Volatility (annualised)144.5%
Price vs SMA 50-48.1%
Price vs SMA 200-74.4%

Monthly Close (12 months)

MonthCloseChange
2025-10$27.90
2025-11$24.84-11.0%
2025-12$9.43-62.0%
2026-01$7.27-22.9%
2026-02$7.32+0.7%
2026-03$4.27-41.7%
2026-04$4.85+13.6%
2026-05$4.91+1.2%
2026-06$4.44-9.6%
2026-07$4.11-7.4%
2026-08$2.44-40.6%
2026-09$1.72-29.5%

Upcoming Earnings

DateEPS Est.Revenue Est.
2026-09-14$-2.53
2026-09-14$159M
2026-09-14$-0.26$14M
2026-09-14
2026-09-14$0.84$26M
2026-09-14

Price

Price$1.72
Market Cap$4M
ExchangeNASDAQ
CountryUS

Valuation Ratios

Price / Book0.24
EV / EBITDA0.07
Dividend Yield0.00%

Financial Health

Debt / Equity0.70
Current Ratio2.08

Related companies: ABP · BCDA · CERO · EPIX · ERNA · HCWB · INAB

Explore sector: Healthcare · Biotechnology

More sections of APVO: Overview · Financials · Valuation · Statistics · Estimates · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks